ALRN
NASDAQAileron Therapeutics Inc.
Latest news
25 items- SECSEC Form 8-K filed by Aileron Therapeutics Inc.8-K - Rein Therapeutics, Inc. (0001420565) (Filer)
- PRAileron Therapeutics Announces Rebranding to Rein TherapeuticsRebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets Company shares to begin trading on Nasdaq under the trading symbol "RNTX" effective January 13, 2025 AUSTIN, Texas, Jan. 10, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), formerly known as Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has changed its name to Rein Therapeutics, Inc. The new
- INSIDERPresident and CEO Windsor James Brian bought $898 worth of shares (400 units at $2.24) (SEC Form 4)4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)
- INSIDERSEC Form 4 filed by Director Aivado Manuel4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)
- INSIDERSEC Form 4 filed by Director Ambros Reinhard J.4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)
- INSIDERSEC Form 4 filed by Director Fairey William4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)
- INSIDERSEC Form 4 filed by Director Von Rickenbach Josef H4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)
- INSIDERSEC Form 4 filed by Director Musso Alan A4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Windsor James Brian4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)
- PRAileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsAnnounced promising safety and positive biomarker data from Cohort 2 (5mg BID) of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients demonstrating dose dependent effects in five biomarkers evaluated compared to low dose LTI-03 Data from Cohort 2 of the Phase 1b clinical trial confirms results from Cohort 1, with four biomarkers achieving statistical significance in the combined Cohort 1 and Cohort 2 data set Planning is underway for a Phase 2 clinical trial AUSTIN, Texas, Nov. 14, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significan
- SECSEC Form 8-K filed by Aileron Therapeutics Inc.8-K - Aileron Therapeutics, Inc. (0001420565) (Filer)
- SECSEC Form 10-Q filed by Aileron Therapeutics Inc.10-Q - Aileron Therapeutics, Inc. (0001420565) (Filer)
- PRAileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and decreased the expression of a biomarker indicative of epithelial health and lung function decline, suggesting potential therapeutic effect Positive trend observed in seven out of eight IPF biomarkers in Cohort 2, with four biomarkers statistically significant in the combined Cohort 1 and Cohort 2 data set, and dose dependent movement of five biomarkers compared to low dose LTI-03 indicative of active LTI-03 pharmacodynamics High-dose LTI-03 was well-tolerated, with no safety signals observed Planning is underway for a Phase 2
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aileron Therapeutics Inc.SCHEDULE 13G/A - Aileron Therapeutics, Inc. (0001420565) (Subject)
- PRAileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway FibrosisFirst scientific presentation of previously announced data from Cohort 1 of the ongoing Phase 1b clinical trial evaluating low-dose LTI-03 (2.5 mg BID) in IPF, affirms positive trends in seven of the eight biomarkers evaluated, suggesting potential therapeutic effect Recently completed enrollment of Cohort 2 evaluating high-dose LTI-03 (5 mg BID) in mid-September; topline data expected in the near-term AUSTIN, Texas, Oct. 12, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the pr
- PRAileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)Cohort 2 will evaluate high-dose LTI-03 (5 mg BID) Previously announced Cohort 1 data demonstrated positive trends in seven of the eight biomarkers evaluated, suggesting a potential therapeutic effect AUSTIN, Texas, Sept. 23, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the completion of enrollment in Cohort 2 of the ongoing Phase 1b clinical trial of LTI-03 in IPF patients.
- INSIDERSEC Form 4 filed by Director Aivado Manuel4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)
- INSIDERSEC Form 4 filed by Director Von Rickenbach Josef H4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)
- INSIDERSEC Form 4 filed by Director Fairey William4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)
- INSIDERSEC Form 4 filed by Director Ambros Reinhard J.4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)
- INSIDERSEC Form 4 filed by Director Musso Alan A4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)
- SECSEC Form 8-K filed by Aileron Therapeutics Inc.8-K - Aileron Therapeutics, Inc. (0001420565) (Filer)
- PRAileron Therapeutics to Present at the 8th Annual IPF SummitAUSTIN, Texas, Aug. 19, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer of Aileron, will present at the 8th Annual IPF Summit taking place August 20-22, 2024 in Boston, MA. Details of the presentation are as follows: Presentation Title: Biomarker Strategies in the Clinical Development of LTI-03 in IPFS
- PRAileron Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsAnnounced positive data from Cohort 1 of the ongoing Phase 1b clinical trial of LTI-03 evaluating low dose LTI-03 (2.5 mg BID) in idiopathic pulmonary fibrosis ("IPF") patients, with positive trends observed in seven of the eight biomarkers evaluated Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in the third quarter of 2024 AUSTIN, Texas, Aug. 14, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ:ALRN), a biopharmaceutical company advancing a pipeline of potential first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the second qu
- SECAileron Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Aileron Therapeutics, Inc. (0001420565) (Filer)
ALRN FAQ
6 questionsWhat does Aileron Therapeutics Inc. do?
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications...Where does ALRN stock trade?
Aileron Therapeutics Inc. (ALRN) is listed on NASDAQ.What sector and industry is ALRN in?
Aileron Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aileron Therapeutics Inc. go public?
Aileron Therapeutics Inc. (ALRN) completed its IPO in 2017.What companies are similar to ALRN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ALRN side-by-side with any of them on Quantisnow.How can I track ALRN on Quantisnow?
Quantisnow aggregates Aileron Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALRN to receive live email and push alerts on every new disclosure.